Annexon (NASDAQ:ANNX) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Annexon (NASDAQ:ANNX) released its quarterly earnings data on Monday. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05), Zacks reports.

Annexon Stock Performance

Shares of ANNX stock opened at $2.47 on Wednesday. The company has a market capitalization of $263.29 million, a P/E ratio of -2.35 and a beta of 1.07. The company’s 50 day moving average price is $3.90 and its two-hundred day moving average price is $5.39. Annexon has a 52 week low of $2.30 and a 52 week high of $8.40.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.